Feasibility and efficacy of sublingual buprenorphine tablets in managing acute postoperative pain after elective breast cancer surgeries: A series of 10 cases

Autor: Basanth Kumar Rayani, Srinivasa Shyam Prasad Mantha, D Krishna Sumanth, Abhijit S Nair
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Indian Journal of Anaesthesia
Indian Journal of Anaesthesia, Vol 63, Iss 12, Pp 1036-1038 (2019)
ISSN: 0976-2817
0019-5049
Popis: Poorly controlled perioperative surgical pain is a consistent risk factor for developing post mastectomy pain syndrome (PMPS).[1] The incidence of chronic pain after mastectomy is as high as 25-60%, which is a range derived from several studies.[2] American Society of Anesthesiologists (ASA) recommends a multimodal approach to postoperative pain management whenever possible which includes use of non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, alpha-2 agonists, N-methyl D-aspartate receptor antagonists, gabapentinoids, dexamethasone, anti-depressants and peripheral nerve blocks.[3] Buprenorphine hydrochloride is a partial μ-receptor agonist, OLR-1 (Oxidized Low-density lipoprotein Receptor) agonist, delta and kappa receptor antagonist approved for managing acute surgical pain, cancer pain and non-cancer pain.[4] Sublingual (SL) buprenorphine is available in the form of 200 μg tablets which has been used with good results for managing acute postoperative pain.[5] In the present case series, we have investigated the feasibility and efficacy of SL buprenorphine in managing acute postoperative pain after mastectomy.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje